Purpose We investigated the correlation of 18F-AlF-NOTAPRGD2 (18F-RGD) uptake during
positron emission tomography (PET) with tumoral programmed death-ligand 1 (PD-L1) …

Aim: We evaluated the metabolic characteristics of small-sized lung cancer using 18F-
fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG …

Background: Tumor PD-L1 IHC relates moderately with treatment outcome following anti-
PD1 therapy in pts with NSCLC and single biopsies do not account for tumor heterogeneity …

Objective The uptake of 18 F-fluorodeoxyglucose (18 F-FDG) PET/computed tomography
(CT) is known to be linked to programmed death ligand 1 (PD-L1) expression on tumor cells …

Objectives Programmed cell death-ligand 1 (PD-L1) is expressed on tumor cells (TC) and
tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the …

Background This study aimed to determine the relationship of programmed death-ligand 1
(PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron …

Rarely before has a novel cancer treatment led to such an explosion in molecular imaging
research as has been seen in recent years with immunotherapy [1–3]. In fact, over 700 …

Purpose Immunotherapy aimed at inhibiting the PD-1/PD-L1 immune checkpoint has been
approved and used successfully for the treatment of bladder cancer. The identification of …

Objectives. Immune checkpoint blockers constitute the first‐line treatment for advanced non‐
small‐cell lung cancer (NSCLC) with≥ 50% PD‐L1 expression. In NSCLC, PD‐L1 positivity …

Purpose Tumor heterogeneity limits the predictive value of PD-L1 expression and influences
the outcomes of the immunohistochemical assay for therapy-induced changes in PD-L1 …